Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $446.4 million specializing in mRNA therapeutics and vaccines, stands at a ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" ...

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...

After hours: January 28 at 5:53:48 PM EST ...

URWERK, renowned for its innovative and futuristic timepieces, has unveiled its newest iteration of the UR-100V Magic T ...